Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States.

Crohns Colitis 360 · 2021 · PMC9802363 · PMID 36776661

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

23 They reported similar equivalency results; however, the infliximab-dyyb group did not reach statistical significance for the composite outcome (HR 1.04; 95% CI 0.94–1.15) but did for a serious infections safety outcome (HR 0.65; 95% CI 0.48–0.88).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.